Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04629729 · ClinicalTrials.gov registry record · Phase 1

FT819 in Subjects With B-cell Malignancies

A Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, B-Cell, sponsored by Fate Therapeutics.

Active
Registry status
Phase 1
Development phase
54
Enrollment target
18
Study locations

NCT04629729 is a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, B-Cell that is active but no longer recruiting, run by Fate Therapeutics. The registered enrollment target is 54 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% lower). The trial reports 18 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04629729, a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, B-Cell, is active but no longer recruiting, sponsored by Fate Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
54 participants
Enrollment target
18
Study locations

Study Summary

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Conditions Studied

Chronic Lymphocytic Leukemia Lymphoma, B-Cell Precursor B-Cell Acute Lymphoblastic Leukemia

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG IL-2
  • DRUG Bendamustine
  • DRUG FT819

Study Locations (18)

California

  • UC Davis - Davis
  • Scripps Green Hospital - La Jolla
  • UCLA Ronald Reagan Medical Center - Los Angeles
  • Stanford Cancer Institute - Palo Alto

Florida

  • University of Florida - Gainesville
  • Mayo Florida - Jacksonville

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Arizona - Phoenix

Iowa

  • University of Iowa - Iowa City

Kansas

  • The University of Kansas Cancer Center - Westwood

Kentucky

  • Norton Cancer Institute, St. Matthews Campus - Louisville

Minnesota

  • Mayo Minnesota - Rochester

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2021-07-12
Est. Completion 2039-09-30
Phase Phase 1

Sponsor

Fate Therapeutics

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04629729

The ClinicalTrials.gov registry entry for NCT04629729 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% lower). The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT04629729 reports 18 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT04629729 about?

NCT04629729 is a clinical study titled "FT819 in Subjects With B-cell Malignancies". This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage whe...

What is the current status of trial NCT04629729?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2021-07-12. Estimated completion is 2039-09-30.

What conditions does trial NCT04629729 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Lymphoma, B-Cell, Precursor B-Cell Acute Lymphoblastic Leukemia.

What interventions are being tested in trial NCT04629729?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IL-2 (DRUG), Bendamustine (DRUG), FT819 (DRUG).

Who is sponsoring clinical trial NCT04629729?

This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04629729 being conducted?

This trial has 18 study locations across Alabama, Arizona, California, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Lymphoma, B-Cell

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.